Pathogenesis of myositis in children

Current Opinion in Rheumatology

Volumn 19, Issue 5, 2007, Pages 487-491

  Griffin, Thomas A ^a,c   Reed, Ann M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Mayo Clinic   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Idiopathic inflammatory myopathies; Juvenile dermatomyositis; Plasmacytoid dendritic cells; Type I interferons

Indexed keywords

BIOLOGICAL MARKER; CD83 ANTIGEN; CHEMOKINE; INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MYXOVIRUS RESISTANCE PROTEIN A; TOLL LIKE RECEPTOR;

CELL INFILTRATION; CELL MATURATION; CELL SURVIVAL; CYTOTOXICITY; DENDRITIC CELL; DERMATOMYOSITIS; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INFLAMMATORY CELL; INNATE IMMUNITY; JUVENILE DERMATOMYOSITIS; MYOPATHY; MYOSITIS; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UPREGULATION;

CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DERMATOMYOSITIS; GTP-BINDING PROTEINS; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE I;

EID: 34548335104     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32825a6a57     Document Type: Review

References (39)

1. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathies. Autoimmunity 2006; 39:161-170.
2. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-336.
3. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168:4154-4163.
4. Bakay M, Wang Z, Melcon G, et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006; 129:996-1013. This study included publicly available gene expression profiles of muscle tissue from 21 children with juvenile dermatomyositis, which is the largest published microarray cohort for this disease. The data are available through the PEPR portal at pepr.cnmcresearch.org.
5. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170-1182.
6. Zhou X, Dimachkie MM, Xiong M, et al. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit 2004; 10:BR191-BR197.
7. Tian L, Greenberg SA, Kong SW, et al. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005; 102:13544-13549.
8. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128:1887-1896.
9. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-α/ β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664-678.
10. Wenzel J, Schmidt R, Proelss J, et al. Type I interferon- associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006; 31:576-582.
11. O'Connor KA, Abbott KA, Sabin B, et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006; 120:319-325. This study demonstrated increased expression of a type I interferon-inducible antiviral gene, MxA, in peripheral blood mononuclear cells of patients with dermatomyositis, and suggests that this is a potential biomarker for muscle disease activity.
12. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13:59-68. This study demonstrated a type I interferon gene expression signature in peripheral blood cells of most patients with dermatomyositis, and suggested that the strength of this signature may correlate with disease activity.
13. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-231.
14. Bartoccioni E, Gallucci S, Scuderi F, et al. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994; 95:166-172.
15. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1α expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002; 46:1044-1055.
16. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52:1824-1835.
17. Li CK, Varsani H, Holton JL, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31:605-609.
18. van der Pas J, Hengstman GJ, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75:136-139.
19. Dorph C, Englund P, Nennesmo I, Lundberg IE. Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65:1565-1571.
20. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000; 97:9209-9214.
21. Sugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000; 164:6593-6600.
22. Sugiura T, Harigai M, Kawaguchi Y, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002; 14: 917-924.
23. Fall N, Bove KE, Stringer K, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum 2005; 52:3175-3180.
24. De Paepe B, De Keyzer K, Martin JJ, De Bleecker JL. α-Chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol (Berl) 2005; 109:576-582.
25. Caproni M, Torchia D, Cardinali C, et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 2004; 151:784-791.
26. Liprandi A, Bartoli C, Figarella-Branger D, et al. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol (Berl) 1999; 97:642-648.
27. Confalonieri P, Bernasconi P, Megna P, et al. Increased expression of b-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000; 59:164-169.
28. De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 2002; 58:1779-1785.
29. Civatte M, Bartoli C, Schleinitz N, et al. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005; 31:70-79.
30. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005; 202:135-143.
31. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-1837.
32. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004; 50:199-208.
33. Nagaraju K, Rider LG, Fan C, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006; 3:2.
34. Lopez de Padilla CM, Vallejo AN, McNallan KT, et al. Plasmacytoid dendritic cells in inflamed muscle of juvenile dermatomyositis. Arthritis Rheum 2007; 56:1658-1668. This study demonstrated the abundance of mature plasmacytoid dendritic cells in affected skeletal muscle tissue from children with juvenile dermatomyositis.
35. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35:17-23.
36. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113:407-414.
37. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
38. Schreiner B, Voss J, Wischhusen J, et al. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. Faseb J 2006; 20:118-120.
39. Tateyama M, Fujihara K, Misu T, et al. Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis. J Neurol Sci 2006; 249:158-165.